You are here
Disease modifying therapies
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.Mult Scler. 2013 Nov 8. [Epub ahead of print]
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.J Neurol Neurosurg Psychiatry. 2013 Sep 12. [Epub ahead of print]
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study.Mult Scler. 2013 Nov 4. [Epub ahead of print]
- Cochrane Database Syst Rev. 2013 Jun 6;6:CD008933.
Impact of Disease-Modifying Therapies on the Survival of Patients with Multiple Sclerosis in Taiwan, 1997–2008Clinical Drug Investigation, September 2013, Volume 33, Issue 9, pp 647-652
Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.Ann Neurol. 2013 Sep 5. doi: 10.1002/ana.24018. [Epub ahead of print]
- Neurology. 2013 Sep 3;81(10):872-6. doi: 10.1212/WNL.0b013e3182a35215.
- Ann Neurol. 2013 Aug 16. doi: 10.1002/ana.24009. [Epub ahead of print]